Fate Therapeutics (FATE) PT Lowered to $7 at Leerink Partners
Tweet Send to a Friend
Leerink Partners analyst Daina Graybosch lowered the price target on Fate Therapeutics (NASDAQ: FATE) to $7.00 (from $12.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
